821 related articles for article (PubMed ID: 26543084)
21. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
22. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
23. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
25. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
27. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
McCann KE; Hurvitz SA; McAndrew N
Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
[TBL] [Abstract][Full Text] [Related]
28. Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
[TBL] [Abstract][Full Text] [Related]
29. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.
Musolino A; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Vattiato R; Sgargi P; Falcini F; Caminiti C; Michiara M; Leonardi F
Cancer Treat Rev; 2016 Feb; 43():1-7. PubMed ID: 26827687
[TBL] [Abstract][Full Text] [Related]
30. [New targeted therapies in breast cancer].
Coussy F; Teixeira L; Giacchetti S; Cuvier C; Hocini H; Espié M
Gynecol Obstet Fertil; 2014 Nov; 42(11):787-94. PubMed ID: 25442825
[TBL] [Abstract][Full Text] [Related]
31. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
32. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
33. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
34. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
35. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
[TBL] [Abstract][Full Text] [Related]
36. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
38. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
39. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
40. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
von Minckwitz G; Loibl S; Maisch A; Untch M
Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]